- Coalition Comments to FDA re Labeling for Biosimilar Products (August 2016)
- Letter to State Dept re Intellectual Property & Access to Medicines (July 2016)
- Letter to Senate HELP Cmte Leaders re 21st Century Cures (May 2016)
- Coalition Comments to FDA re Direct-to-Consumer Advertising (April 2016)
- NPA Comments on FDA Generics Labeling to US House Appropriation and Agriculture Committees (April 2016)
- US TPP public health letter (April 2016)
- FOCR sign on letter regarding regulation of laboratory developed tests (LDT)_Senate (April 2016)
- FOCR sign on letter regarding regulation of laboratory developed tests (LDT)_House (April 2016)
- Non-Profit Groups Urge Obama Administrations, NIH to Lower Price of Government-Funded $129,000 Per Year Prostate Cancer Drug (March 2016)
- Comments of members of the Patient, Consumer, and Public Health Coalition on the FDA Draft Guidance entitled “Over-the-Counter Sunscreens: Safety and Effectiveness Data” (March 2016)
- Comments on Proposed Rule: Restricted Sale, Distribution, and Use of Sunlamp Products (March 2016)
- NPA comments re tanning beds, Docket ID FDA-2015-N-1765 (March 2016)
- NPA Recommends Enhancements to FDA’s Opioid Action Plan (Feb 2016)
- NPA Comments to Senator Murray re Senate HELP Preventable Tragedies Report (Jan 2016)
- NPA Comments re CDC Opioid Guidelines (Jan 2016)
- Comments of members of the Patient, Consumer, and Public Health Coalition on Medical Device Patient Labeling (October 2015)
- FedUP Coalition Letter to Senate Finance Committee (September 2015)
- Coalition Letter on 21st Century Cures draft legislation (May 2015)
- Letter Regarding Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (April 2015)
- Comments at the FDA Meeting to Discuss Proposed Rule that Would Allow Manufacturers of Generic Medications to Autonomously Update Their Product Label (March 2015)
- Letter in Support of the ACA and the Medical Device Tax (Jan 2015)
- Comments of members of the Patient, Consumer, and Public Health Coalition on the proposed order on Reclassification of Iontophoresis Devices Intended for Any Other Purposes (Dec 2014)
- Letter to Commissioner Hamburg re FDA Advisory Committees and Hearings (Dec 2014)
- Comments of members of the Patient, Consumer, and Public Health Coalition on the proposed order to reclassify External Pacemaker Pulse Generator devices and Pacing System Analyzers (Dec 2014)
- Chantix Petition (Oct 2014)
- NPA comments re Draft Guidance, “Intent to Exempt Certain Class II and Class I Reserved Medical Devices from Premarket Notification Requirements” (Oct 2014)
- NPA comments re the Proposed Rule, “Medical Device Classification Procedures” (Sept 2014)
- NPA comments re FDA draft guidance on correcting misinformation on social media (Sept 2014)
- Letter in support of the FDA’s proposed regulations to allow generic drug makers to initiate safety updates to their product labels(Sept 2014)
- Draft guidance for industry on distributing scientific and medical publications on risk information for approved prescription drugs and biologic products (August 2014)
- Comment on the FDA’s proposed rules to extend its authority to regulate electronic cigarettes under the Tobacco Control Act (August 2014)
- Letter to Congressman Cooper re Research for All Act (June 2014)
- Letter to House Appropriations Chair & Ranking Member re opposition to Cigar Exemption from FDA regulation (May 2014)
- Comments on Voluntary 2015 Edition Electronic Health Record Certification Criteria: Interoperability Updates and Regulatory Improvements (April 2014)
- Letter to Dr Hamburg re HPV Test (April 2014)
- Letter in support of the unique device identifier (UDI) in claims transmissions (March 2014)
- Letter of support for Congresswoman Slaughter’s antibiotics bill(March 2014)
- NPA Letter opposing the Antibiotic Development to Advance Patient Treatment Act of 2013 (ADAPT), H.R. 3742, to members of U.S. House Energy & Commerce Sub Committee on Health, and U.S. Senate Health, Education, Labor & Pension Committee (Feb2014)
- Comments to FDA re proposed changes to labeling for approved drugs & biologics (Feb2014)
- Letter to Congresswoman Rosa DeLauro in support of strengthening FDA safeguards (Feb 2014)
- Comments submitted to FDA re draft guidance on pharmacy compounding (Feb 2014)
- Letter submitted to FDA re: Proposing Labeling Changes for Approved Drugs and Biological Products (January 2014)
- Letter submitted to FDA re: down-classification of cardiac device (September 2013)
- Comments submitted to FDA re: antibacterial drug development (Aug 2013)
- Comments submitted to FDA re: risk categorization of cardiac devices (Aug 2013)
- Comments submitted to FDA re: proposed Alternative Pathway for Drug Approvals (Jan 2013)
- Letter to FDA in support of Unique Device Identifier system (Nov 2012)
- Letter to FDA Commissioner re Conflict of Interest Restrictions for advisory panels (Aug 2011)
- Letter to FDA re: Medical Device User Fee Act reauthorization process (Jul 2011)
